INT10116

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1992
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 5.43
Pain Relevance 3.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (INSR) endosome (INSR) plasma membrane (INSR)
nucleus (INSR) carbohydrate metabolic process (INSR)
Anatomy Link Frequency
plasma 2
neurons 1
fat cells 1
INSR (Homo sapiens)
Pain Link Frequency Relevance Heat
tramadol 240 100.00 Very High Very High Very High
cINOD 48 96.88 Very High Very High Very High
Pain 107 94.28 High High
GABA receptor 15 94.20 High High
Serotonin 8 90.56 High High
gABA 6 90.00 High High
opioid receptor 12 88.36 High High
Analgesic 56 86.72 High High
opiate 2 84.52 Quite High
COX-2 inhibitor 26 77.96 Quite High
Disease Link Frequency Relevance Heat
Obesity 66 99.88 Very High Very High Very High
Sleep Disorders 187 99.76 Very High Very High Very High
Disease 18 97.96 Very High Very High Very High
Disorders Of Creatine Metabolism 7 97.00 Very High Very High Very High
Insulin Resistance 9 96.84 Very High Very High Very High
Pain 188 94.28 High High
Diabetes Mellitus 49 91.76 High High
Hemorrhage 4 82.64 Quite High
Renal Insufficiency 4 70.48 Quite High
Impaired Glucose Tolerance 3 68.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These findings are consistent with a pituitary source for the elevated plasma beta E IR found during late pregnancy which may, in turn, be a consequence of elevated plasma concentrations of placentally secreted plasma corticotropin-releasing factor IR present during the third trimester.
Localization (secreted) of factor IR in plasma
1) Confidence 0.57 Published 1992 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 1464647 Disease Relevance 0 Pain Relevance 0.08
OBJECTIVE: To review the pharmacodynamics, pharmacokinetics, efficacy, tolerability, dosing, and role of oral oxymorphone immediate-release (IR) and extended-release (ER).
Localization (release) of IR
2) Confidence 0.49 Published 2007 Journal Consult Pharm Section Abstract Doc Link 17658959 Disease Relevance 0 Pain Relevance 0
At the plasma membrane of adipocytes, the IR has been shown to be localized in plasma membrane microdomains, invaginations of the membrane, referred to as caveolae [2].
Localization (localized) of IR in plasma associated with obesity
3) Confidence 0.26 Published 2008 Journal PLoS Computational Biology Section Body Doc Link PMC2424138 Disease Relevance 0.43 Pain Relevance 0
It is important that in human fat cells, but for instance not in rat adipocytes, the IRS1 is co-localized with the IR in caveolae [3].
Neg (not) Localization (localized) of IR in fat cells associated with obesity
4) Confidence 0.24 Published 2008 Journal PLoS Computational Biology Section Body Doc Link PMC2424138 Disease Relevance 0.38 Pain Relevance 0
Immediate-release (IR) tramadol is initiated at 25 mg and titrated in 25 mg increments over 3 days to achieve 25 mg four times daily (qid), then in 50 mg increments over 3 days to 50 mg qid (Ultram PI 2004).
Localization (Immediate-release) of IR associated with tramadol
5) Confidence 0.13 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386353 Disease Relevance 0.96 Pain Relevance 1.52
Tramadol ER vs tramadol IR
Localization (tramadol) of IR associated with tramadol
6) Confidence 0.11 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386353 Disease Relevance 0.66 Pain Relevance 1.68
However, it was not possible to demonstrate correlation of visfatin with HOMA-IR [20,23].
Localization (correlation) of HOMA-IR
7) Confidence 0.10 Published 2010 Journal Diabetol Metab Syndr Section Body Doc Link PMC2857825 Disease Relevance 1.47 Pain Relevance 0
Indiplon-IR (immediate release) was designed to address sleep onset difficulties, both at the beginning of the night and after middle of the night awakenings.
Localization (release) of Indiplon-IR
8) Confidence 0.05 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656319 Disease Relevance 0.34 Pain Relevance 0.08
Indiplon was developed in two different formulations to address two different types of insomnia complaint: indiplon-IR (immediate release) was designed for sleep onset difficulties, while indiplon-MR (modified release) was developed for sleep maintenance insomnia.
Localization (release) of indiplon-IR associated with sleep disorders
9) Confidence 0.05 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656319 Disease Relevance 0.67 Pain Relevance 0.04
Localization of GnIH-ir neurons in the human hypothalamus
Localization (Localization) of GnIH-ir in neurons
10) Confidence 0.04 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2791420 Disease Relevance 0 Pain Relevance 0.04
Indiplon was developed in two different formulations to address two different types of insomnia complaint: indiplon-IR (immediate release) was designed for sleep onset difficulties, while indiplon-MR (modified release) was developed for sleep maintenance insomnia.
Localization (release) of indiplon-IR associated with sleep disorders
11) Confidence 0.04 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Abstract Doc Link PMC2656319 Disease Relevance 0.53 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox